The present invention relates to modified monosaccharide compounds implemented in methods for labeling and/or detecting an eukaryotic cell from a multicellular organism. It also relates to such modified monosaccharide compounds implemented in methods for identifying or isolating cancer cells, diagnosing a cancer or for cell therapy.

The present invention relates to a novel antibody which binds to CTHRC1 and use thereof.

The present invention relates to methods of identifying a subject for treatment with or treating a subject with a tricyclic AKR1C3 dependent KARS inhibitor of formula (I), or a pharmaceutically acceptable salt thereof. The methods may comprise determining in a subject sample a level of at least one of the following biomarkers: AKR1C3, NFE2L2, KEAP1, or CUL3, wherein an elevated level of the biomarker identifies the subject as being in need of treatment; or detecting in a subject sample a somatic mutation in at least one of the following genes: NFE2L2, KEAP1, or CUL3, wherein detecting the somatic mutation identifies the subject as being in need of treatment.

The present invention provides an antibody or an antigen-binding fragment thereof that is useful for testing for cancer, particularly early-stage cancer. The antibody or an antigen-binding fragment thereof comprises a heavy-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a heavy-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, a light-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SAS, and a light-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Provided are a cancer therapeutic drug comprising a compound which inhibits GPX4 as an active ingredient, the cancer therapeutic drug treating cancer containing a cancer cell having a suppressed function of a SWI/SNF complex factor detected; and a method for predicting sensitivity of a cancer cell to a GPX4 inhibitor, the method comprising the step of predicting a cancer cell having a suppressed function of a SWI/SNF complex factor detected in the cancer cell, as having sensitivity to the GPX4 inhibitor.

This document relates to materials and methods for assessing and/or treating subjects (e.g., subjects having autoimmune diseases). For example, materials and methods for determining if a subject (e.g., a human having an autoimmune disease) has one or more antibodies that can be used to identify the subject as having a lower risk of cancer or as having a higher risk of cancer are provided. Materials and methods for treating a subject (e.g., a human) identified as having a higher cancer risk for cancer are also provided.

The invention relates to the measurement of cell free nucleosomes for the selection of biological samples for DNA sequencing. The invention also relates to using the measurement of cell free nucleosomes to determine the volume of body fluid sample required to obtain a required level of DNA for DNA sequencing.

The present invention relates to monoclonal antibodies that target collagen type XIX and to the sequences of the complementarity-determining regions distinguishing the monoclonal antibodies. Also, the present invention relates to immunoassays and to kits employing the antibodies. The assays of the invention are used in the diagnosis and monitoring of cancer.

The present disclosure provides methods of treating multiple myeloma in a patient in need thereof comprising administering a gamma secretase and a B-cell maturation antigen (BCMA)-directed therapy to the patient.

The present invention pertains to a multiple biomarker for cancer diagnosis and a use thereof and, specifically, to a composition for cancer diagnosis, comprising an agent for measuring the protein or mRNA expression levels of IGFI, KLK2, PKC, and TRPM8. The present inventors confirmed that rapid and accurate cancer diagnosis can be performed by detecting the unique marker combination of IGFI, KLK2, PKC, and TRPM8 of the present invention in serum samples from actual cancer patients and one or more cancers can be simultaneously detected. Thus, the combination of IGFI, KLK2, PKC, and TRPM8 is expected to allow for the rapid and accurate diagnosis of various cancers including prostate cancer.